GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Return-on-Tangible-Equity

Verici Dx (Verici Dx) Return-on-Tangible-Equity : -148.64% (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Verici Dx's annualized net income for the quarter that ended in Jun. 2023 was $-10.55 Mil. Verici Dx's average shareholder tangible equity for the quarter that ended in Jun. 2023 was $7.10 Mil. Therefore, Verici Dx's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 was -148.64%.

The historical rank and industry rank for Verici Dx's Return-on-Tangible-Equity or its related term are showing as below:

VRCDF' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -122.13   Med: -91.19   Max: -60.25
Current: -112.05

During the past 3 years, Verici Dx's highest Return-on-Tangible-Equity was -60.25%. The lowest was -122.13%. And the median was -91.19%.

VRCDF's Return-on-Tangible-Equity is ranked worse than
84.24% of 203 companies
in the Medical Diagnostics & Research industry
Industry Median: -0.63 vs VRCDF: -112.05

Verici Dx Return-on-Tangible-Equity Historical Data

The historical data trend for Verici Dx's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Return-on-Tangible-Equity Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22
Return-on-Tangible-Equity
- -59.85 -116.89

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23
Return-on-Tangible-Equity -37.09 -86.84 -85.27 -94.26 -148.64

Competitive Comparison of Verici Dx's Return-on-Tangible-Equity

For the Diagnostics & Research subindustry, Verici Dx's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verici Dx's Return-on-Tangible-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Verici Dx's Return-on-Tangible-Equity falls into.



Verici Dx Return-on-Tangible-Equity Calculation

Verici Dx's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-11.407/( (9.978+9.539 )/ 2 )
=-11.407/9.7585
=-116.89 %

Verici Dx's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=-10.546/( (9.539+4.651)/ 2 )
=-10.546/7.095
=-148.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Verici Dx  (OTCPK:VRCDF) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Verici Dx Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Verici Dx's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx (Verici Dx) Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines